

84

**Topiramate prophylaxis in patients suffering from migraine with aura results from a randomized, double blind, placebo-controlled trial**

F Freitag<sup>1</sup> S D Silberstein<sup>1</sup> R Karim<sup>2</sup> M Kamun<sup>2</sup>  
D Jordan<sup>2</sup> & J Hulihan<sup>2</sup>

<sup>1</sup>Diamond Headache Clinic Chicago Ill USA <sup>2</sup>Ortho-McNeil  
Pharmaceutical Raritan NJ USA

**Introduction** Topiramate a broad spectrum antiepileptic drug has demonstrated efficacy in migraine prophylaxis in several pilot trials

**Methods** We conducted a multicenter randomized double-blind placebo-controlled study of topiramate in migraine prophylaxis A total of 213 patients were initially randomized in a 2:1 ratio to topiramate or placebo Study medication was titrated weekly in 25-mg increments over 8 weeks to 200 mg/day or to the maximum tolerated dose followed by a 12 week maintenance period A subset of patients ( $n=75$ ) experienced aura or migraine with aura ( $n=46$  topiramate  $n=29$  placebo) at some point during the trial The protocol defined analyses used ANCOVA with baseline monthly migraine rate as covariate

**Results** For the ITT population ( $n=211$ ) the protocol defined repeated measures analyses were not sensitive enough to detect drug placebo differences Among patients with any aura topiramate treated patients exhibited a significantly greater reduction in monthly migraine rate ( $P=0.018$ ) and migraine days/month ( $P=0.04$ ) compared to placebo treated patients

**Conclusions** The results of this study suggest that migraine prophylaxis with topiramate may be more effective in patients with aura compared to those without aura